Skip to main content
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · SABS ISIN · US0891152086 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US SABS

About SAB Biotherapeutics, Inc.

https://www.sab.bio/

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a novel class of immunotherapies. The company's proprietary platform produces targeted, high-potency, fully human polyclonal antibodies without the need for human donors. This technology utilizes transgenic cattle to generate natural human antibodies in response to specific disease targets. The company's lead product candidate, SAB-142, is a disease-modifying immunotherapy being developed to delay the onset and progression of Type 1 Diabetes (T1D) by addressing the underlying autoimmune cause. SAB's development pipeline also includes programs targeting infectious diseases, such as severe influenza and antibiotic resistance.

Recent filings

Filing Released Lang Actions
10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K "Current Report" filed with the SEC describing "Item 1.01 Entry into a Material Definitive Agreement" (Master Manufacturing Services Agreement). It is not an annual or interim report, not a call transcript, not an earnings release, and contains no financial statements in full. It is a regulatory compliance filing under the Exchange Act and thus falls under the general "Regulatory Filings" category.
2026-05-04 English
8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text indicates that the company made available a presentation and issued a press release regarding clinical trial data. The document includes references to exhibits containing the press release and the presentation. There are no detailed financial statements or comprehensive financial analysis present in the text. The document is about disclosing new information rather than providing a full financial report or earnings release. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-22 English
S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form S-8 filing, which is a registration statement used by companies to register securities to be offered under employee benefit plans. The content includes detailed tables calculating the filing fee for newly registered securities under an equity incentive plan. It does not contain financial statements, management discussion, or earnings data. It is not an announcement or a report but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and focused on fee calculation tables, confirming it is not a full report or announcement.
2026-03-31 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.